Generic Allegra Only 120mg x 90 pills $99.55
Lowest price on medication. Discreet Packing Fast Worldwide Delivery.
www.all-tablet.com
Cheap Generic Allegra Only 120mg x 120 pills $130.10 US
Best Drugstore. No rx prescription needed. Privacy!
www.tadalafiltrusted.com
Taking nonsteroidal anti-inflammatory drugs (NSAIDs) from a young age might prevent early signs of Alzheimer’s disease, according to the results of a new study in mice.
Recent research suggests that the appearance of neuronal cell cycle events (CCEs) occurs early in the development of Alzheimer’s. In the new study, U.S. researchers looking for triggers of neuronal CCEs found evidence that suggests that neuroinflammation plays a role in the development of Alzheimer’s in mice.
Administration of the inflammatory molecule LPS triggered the early appearance of neuronal CCEs, the researchers found, and treatment with the NSAIDs ibuprofen or naproxen blocked the development of CCEs.
In older mice, treatment with NSAIDs prevented new neuronal CCEs but did not affect existing CCEs, the study authors noted.
The study, published online Nov. 9 in the Journal of Clinical Investigation, offers a potential explanation for findings in humans that long-term NSAID use protects against Alzheimer’s but does not benefit people who already have mild to moderate Alzheimer’s disease.
Micardis (telmisartan) has received expanded approval from the U.S. Food and Drug Administration to reduce the risk of heart attack or stroke in people 55 or older who cannot take a class of cardiovascular drugs called ACE inhibitors, maker Boehringer Ingelheim said Monday.
Micardis belongs to its own class called angiotensin II receptor blockers. It’s been available in the United States since 1998 to treat high blood pressure.
The FDA also granted new approval for a drug called Twynsta, which combines the active ingredient in Micardis with the calcium channel blocker amlodipine. The combination drug is meant to prevent high blood pressure when used alone, or in tandem with other anti-hypertension drugs, Boehringer said in a news release.
Some studies estimate that as many as 20 percent of people taking ACE inhibitors have side effects, which could prevent the drugs’ use as prescribed, the company said. Micardis has possible side effects of its own, including upper respiratory infection, back pain, sinusitis and diarrhea. The drug shouldn’t be used by pregnant women, Boehringer said.
Too few resident physicians have been trained in skin cancer examinations or watched or practiced the procedure, U.S. researchers report.
In a survey of 342 resident physicians in family medicine, obstetrics and gynecology, pediatrics and internal medicine, researchers collected information on the participants’ training and experience with skin cancer exams as well as their level of skill in performing the exams.
“Clinical training for the skin cancer examination during residency was infrequent,” wrote Dr. Emily Wise, of the Boston University School of Medicine, and colleagues. “During residency, 75.8 percent were never trained in the skin cancer examination, 55.3 percent never observed a skin cancer examination and 57.4 percent never practiced the examination. Only 15.9 percent of residents reported being skilled in the skin cancer examination.”
The researchers found that performing four skin cancer examinations (about one per year of residency) was associated with improvements in skill levels reported by the respondents.
The findings are published in the October issue of the Archives of Dermatology.
Melanoma is the second-most common cause of cancer in Americans aged 15 to 29. About one-quarter of melanomas are detected by doctors, rather than patients. Skin cancers discovered by doctors are generally thinner and have a better prognosis, according to background information in the study.
“Visits to internists and family practitioners make up an estimated 40 percent of physician visits in the United States, and nearly two-thirds of patients with melanoma report a physician visit in the year before diagnosis. Primary-care physicians are thus ideally suited to screen and triage high-risk patients and those with suspicious lesions,” the study authors wrote.
“Residency programs and medical schools may have neither the time nor the infrastructure to teach an expert, comprehensive examination to all physicians in training,” they concluded. “However, the basic ability to recognize potentially suspicious lesions and triage persons with such lesions should be a vital and key component of both training programs. If current physicians in training do not learn this skill set in medical school or residency, there is a low likelihood that they will acquire this knowledge in their day-to-day practice, which could have potentially devastating consequences for melanoma recognition going forward.”
Researchers say they’ve gained new understanding of how lupus develops in mice, a finding that could help future treatments for the autoimmune disease.
An estimated 1.5 million to 2 million people in the United States suffer from lupus, a disorder in which the body’s defenses turn inward. The condition can cause symptoms similar to those of arthritis and rheumatic diseases.
At issue is the immune system’s ability to take out the trash — to get rid of cells that don’t have long to live. “Just like in mice, in humans, if you don’t clear the dying cells, then that predisposes you to lupus,” said Lata Mukundan, a Stanford University School of Medicine researcher and co-author of a study published online Oct. 18 in the journal Nature Medicine.
“If you look at patients with lupus, they have an inability to clear those dead cells,” Mukundan said in a statement.
The study authors report that they gained insight into how immune-system cells detect which other cells are dying in order to dispose of them. They looked at human and mouse cells outside the body and in genetically engineered mice.
The researchers suspected that a molecule known as PPAR-delta was crucial to the process. “We wanted to know, if you took a mouse and only deleted PPAR-delta from its macrophages, is that sufficient to cause an autoimmune disease?” asked Dr. Ajay Chawla, assistant professor of endocrinology and co-author of the study, in a statement. “Apparently it is,” he said.
The researchers say currently existing drugs activate the molecule in question. Perhaps, they say, the drugs could treat lupus.
A new study finds no differences in blood mercury levels between children who are developing normally and those diagnosed with autism or autism spectrum disorders.
The findings, appearing online Oct. 19 in the journal Environmental Health Perspectives, may quell some of the debate surrounding mercury and autism.
The researchers did not, for instance, look at whether mercury might play a causal role in this group of developmental disorders.
“This is an excellent study that has addressed a very important question for many families about the role of mercury [in autism],” said Dr. Patricia Manning-Courtney, medical director of The Kelly O’Leary Center for Autism Spectrum Disorders at Cincinnati Children’s Hospital Medical Center. “It’s a very clear study [in] that no differences in mercury were seen. Is it going to put the questions to rest? I think no. It’s another important contribution to the large body of knowledge on this topic, but I think it will still be an area of great controversy.”
Previous studies have shown higher blood mercury levels in people with autism, but the results, along with the quality of the studies, have been inconsistent.
One of the biggest controversies claims that vaccines containing the preservative thimerosal, which contains mercury, might cause autism.
But thimerosal is no longer used routinely in children’s vaccines and, earlier this year, a U.S. court ruled that there is no scientific evidence that childhood vaccines such as the measles-mumps-rubella vaccine caused autism in children of parents seeking compensation from a federal fund.
The authors of this study wanted to fill one gap in the research: a lack of good evidence comparing mercury levels in children with autism and children without autism.
The authors looked at 452 children aged 2 to 5, who either had autism/autism spectrum disorder, developmental delays other than autism (such as Down syndrome), or who were developing normally.
Blood samples were taken from the children while mothers answered questions about different possible exposures to mercury, such as diet, dental amalgams, thimerosal-containing vaccines and even personal-care products such as earwax removal systems and nasal sprays.
First results showed that children with autism actually had much lower levels of mercury in their blood, but this was explained by the fact that these children ate less fish.
When the results were adjusted for this and other variables, mercury levels came out about the same between the autism group and the control group.
“Not only do we not see differences, but the values are pretty close to national averages,” said study author Irva Hertz-Picciotto, chief of environmental and occupational health and a faculty member at the MIND Institute at the University of California, Davis.
Overall, children with developmental delays other than autism had lower blood mercury concentrations.
Children who had mercury-based dental fillings who ground their teeth or chewed gum had blood concentrations of the metal. And those few children who had had a mercury-containing vaccine did not show elevations in their blood levels.
“The relationship between [mercury] intake to blood levels seems to follow the pattern that we expect and it’s well known that most of the mercury in the body does come from fish consumption,” Hertz-Picciotto said. “There really were very few children who had vaccines that would have or could have contained thimerosal.”
Most of the children in the study had received vaccines after thimerosal was removed from vaccines, she said.
Mercury only has a half-life in the circulating blood of a few months, Hertz-Picciotto said, so “clearly this does not tell us anything causal because all of the mercury represents exposure that had happened post-diagnosis.”
Sallie Bernard, executive director of SafeMinds (Sensible Action for Ending Mercury-Induced Neurological Disorders), expressed concern about confusing the findings with the interpretation of the findings.
“An interpretation says the study shows no link between mercury and autism, but that’s not what the paper is saying,” Bernard said. “It says they looked to see if [there] was higher exposure in kids with autism after they got their diagnosis. These are current exposures, not what might have happened at an earlier time point in pregnancy or in the first year of life, so you don’t know what affect that might have had.”
The study also does not go into whether certain children may be more susceptible to mercury’s effects, she said.
Vaccination at birth against hepatitis B virus greatly reduces the risk of liver cancer in young adulthood, new research suggests.
In a 20-year study that followed infants who were vaccinated against the liver disease in Taiwan beginning in 1984, when a universal vaccination program went into effect, Dr. Mei-Hwei Chang, of the Department of Pediatrics at the National Taiwan University Hospital in Taipei, and colleagues looked at young people who had developed liver cancer.
The researchers found that only a few people who had been vaccinated developed liver cancer, and there were possible explanations in most cases, such as insufficient doses of the vaccine.
The findings appear in the Sept. 16 online edition of the Journal of the National Cancer Institute.
“These data suggest that the effectiveness of the universal hepatitis B virus immunization program to prevent [liver cancer] has extended beyond childhood and into young adulthood over the past two decades,” the authors concluded.
In the United States, hepatitis B vaccination is recommended for all infants, older children and adolescents if they haven’t previously been vaccinated. Officials recommend that adults get the vaccination if they’re at risk for the disease.
Black patients who suffer cardiac arrest in the hospital are much less likely to survive than white patients, a new study finds.
Most of this disparity appears to result from the hospital in which black patients receive care, although other factors play a role as well, the researchers said.
“We know that survival after having a cardiac arrest in the hospital setting has always been historically low,” said lead researcher Dr. Paul S. Chan, a cardiologist at St. Luke’s Mid-America Heart Institute in Kansas City. “The rate of survival has been about 30 to 33 percent on average.”
But the survival rates for blacks were significantly lower, 25 percent vs. 37 percent for whites, Chan said.
“This 12 percent absolute difference in survival is larger than any survival I can think of in terms of a racial disparity, in any other medical condition,” he said.
The report is published in the Sept. 16 issue of the Journal of the American Medical Association.
For the study, Chan and colleagues used data from the National Registry of Cardiopulmonary Resuscitation to look at differences in survival among patients with in-hospital cardiac arrest.
They collected information on 10,011 patients, about 19 percent of whom were black, from 274 hospitals. These patients had all been defibrillated after a cardiac arrest.
The lower rates of survival to hospital discharge for blacks reflected lower rates of successful resuscitation (55.8 percent for blacks vs. 67.4 percent for whites) and survival after resuscitation (45.2 percent for blacks vs. 55.5 percent for whites), the researchers noted.
About a third of the difference can be explained by the patients themselves, Chan said, “Black patients were sicker when they had a cardiac arrest than white patients,” he said.
Another third of the difference was explained by the hospitals many black patients were in, Chan said.
“This suggests that black patients were having cardiac arrests in hospitals that, on average, did a lot worse, in terms of survival, for all their patients, compared with white patients who went to hospitals that performed better, and patients were more likely to live in those hospitals,” he said.
In addition, the quality of care after resuscitating a patient was worse in hospitals treating mostly black patients compared with care in hospitals treating white patients, Chan said.
“The hospital effect is huge and substantial, and is a contributor to the difference between black and white survival,” he said. “If we can improve survival in those lower-performing hospitals at which black patients are more likely to be having cardiac arrest, we can eventually narrow the difference between black and white survival.”
The remaining difference in survival between blacks and whites could not be explained, Chan said.
There did not seem to be a difference between the treatment blacks and whites received, so racism did not seem to play a role in care between blacks and whites, he said.
“We cannot exclude it fully,” Chan said. “But it’s really hard to imagine that a physician would treat a black patient differently than a white patient during a cardiac arrest.”
Dr. Kim A. Williams, director of nuclear cardiology at the University of Chicago, was surprised that the disparity between blacks and whites wasn’t greater.
“I am truly shocked at the results — only 11 percent less initial resuscitation success,” Williams said. “I thought the differential was far greater than this study demonstrates, but I am not surprised that the results are being attributed, at least in part, to the facilities involved rather than just the co-morbidities of the patients.
“Any attempts to improve this egregious disparity must start with the underlying risks and disease differences identified in this study, which would involve pre-morbid education, prevention and screening, and once risks are identified, better access to affordable chronic care and medications,” he said. “It’s clearly a system problem.”
People with milder symptoms of celiac disease face a slightly higher risk of dying than other people, a new study finds.
Cancer and heart disease were the main causes of death in the patients studied, and the risk was higher in people who had had small-intestinal biopsies in childhood, the researchers found.
Celiac disease affects about 1 percent of people in the Western world, the researchers said, and it is triggered by exposure to gluten, a protein found in barley, wheat and rye. It frequently causes diarrhea and weight loss.
According to the study, which appears in the Sept. 16 issue of the Journal of the American Medical Association, celiac disease is thought to be connected to higher risk of disease, but less is known about “nonspecific small-intestinal inflammation without villous atrophy,” a kind abnormality.
Swedish researchers found the risk of death increased by 39 percent in patients with celiac disease and 35 percent with latent celiac disease.
The research “reinforces the importance of celiac disease as a diagnosis that should be sought by physicians. It also suggests that more attention should be given to the lesser degrees of intestinal inflammation and gluten sensitivity,” wrote Dr. Peter H. R. Green, of Columbia University College of Physicians and Surgeons, in a commentary.
In people with newly diagnosed type 2 diabetes, the glucose-lowering medications metformin and insulin don’t appear to reduce the inflammation associated with heart disease, new research suggests.
Even though these medications helped reduce glucose levels, the researchers found they didn’t affect inflammatory markers any more than a placebo drug did, according to a study published in the Sept. 16 issue of the Journal of the American Medical Association.
“Heart disease is one of the many co-morbidities associated with diabetes,” explained study author Dr. Aruna Pradhan, an assistant professor at the Harvard Medical School and Brigham and Women’s Hospital in Boston, and a cardiologist at the VA Boston Medical Center. “We thought by lowering glucose levels that we would also address inflammation. But, we found that going lower in glucose levels doesn’t impact inflammation, which is a risk factor for heart disease.”
This study comes on the heels of other recent studies on diabetes and cardiovascular disease. Some suggested that intensive glucose control couldn’t affect heart disease risk, while a recent meta-analysis suggests that good blood sugar levels could reduce death from heart attack, according to background information in Pradhan’s study.
Almost 24 million Americans have diabetes, mostly type 2 diabetes, according to the American Diabetes Association. Risk factors for developing the disease include being overweight and being over 40, though younger and thinner people can also develop the disease. In type 2 diabetes, the body either doesn’t produce enough insulin or can’t use insulin effectively.
The current study included 500 men and women with type 2 diabetes diagnosed two years earlier on average. Slightly more women than men were included, and most of the study volunteers had a body-mass index above 30, which is considered obese. The majority of the study participants were white, and about one-quarter of the group were smokers.
The volunteers were randomized into one of four groups: placebo alone, placebo plus insulin glargine (Lantus), metformin (an oral anti-diabetes medication) alone or metformin plus insulin glargine. Study volunteers also received advice on diet and weight.
Overall, the volunteers lost an average of 3.2 pounds during the 14-week study, except for the insulin and placebo group.
As for markers of inflammation, the researchers found reductions in inflammation (as measured through levels of C-reactive protein, IL-6 and tumor necrosis factor receptor 2) for all of the groups. The insulin-plus-placebo group, however, had the smallest reduction in inflammatory markers. For example, C-reactive protein levels went down in the placebo group by 19 percent, in the metformin group by 16 percent and the metformin and insulin group by 20 percent. However, the insulin plus placebo group went down just 3 percent.
Pradhan said the researchers adjusted the data to account for the weight loss, and still found a similar effect. She said it may be that the weight changes affected the distribution of fat, and that abdominal fat tends to have more of an effect on inflammation.
“While these two agents didn’t lower inflammation [any more than the placebo], they did lower glucose levels and are excellent drugs for preventing microvascular outcomes, like eye and kidney diseases,” said Pradhan. The findings also confirm that diet and exercise can affect inflammation levels, she added.
“While this is a well-conducted study, there are no big surprises here,” said Dr. Vivian Fonseca, chief of endocrinology at Scott & White Clinic in Temple, Tex., and Texas A&M Health Sciences Center, College Station. “There are many drugs that benefit people and reduce cardiovascular risk without decreasing inflammation, and there are drugs that reduce inflammation that have sometimes killed people from cardiovascular disease.”
“We’re trying to look at this problem the other way,” said Fonseca. He and other researchers across the country will test an anti-inflammatory medication, salsalate, to see if lowering inflammation directly can have an impact on blood glucose levels.